Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
Key catalysts approach for Orphazyme, Gemini and Immutep.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
Key catalysts approach for Orphazyme, Gemini and Immutep.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.